Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.

#palsonify

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $139 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.
Companies worth $10 billion or more are generally described as "large-cap stocks," and VRTX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. VRTX derives its primary competitive strength from its global monopoly in CF treatments, anchored by flagship blockbusters like Trikafta/Katori which generate robust cash flow to fuel its high-impact clinical pipeline.
Dear GameStop Stock Fans, Mark Your Calendars for September 8
SMCI vs. CoreWeave: 1 AI Infrastructure Model Has the Bigger Opportunity
Why **** ysts Think Sellas Life Sciences Stock Can Gain 150% From Here

#vrtx #massachusetts

Indirect tax and compliance technology company Vertex has made three senior appointments to its leadership team as it prepares for its next stage of expansion.
Chatelle Lynch has joined as chief people officer (CPO) at the company, while Carlos Mercuriali has been named senior vice-president and regional manager for Europe.
The company also announced that Bala Chandran takes up the role of chief product and technology officer.
Lynch has more than 20 years of experience in organisational strategy and transformation-led businesses.
She previously held CPO positions at the RealReal and McAfee.

#technology #officer #vertex

Headquartered in Boston, Massachusetts, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops innovative medicines for serious diseases, including cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain.
Moreover, the company is building beyond its approved treatments with potential therapies targeting genetic and other complex conditions, including kidney, metabolic, and neuromuscular diseases.
Here Is How to Play Tesla Stock After Its Robotaxi Breakthrough
Micron Stock Pullback: High Growth, Low Multiple Support Upside
Strategy Just Sold $334 Million in Shares to Build Cash and Buy Back Preferred Stock. This Hits MSTR Stock Holders With Dilution.

#including #headquartered

Aug 3 (Reuters) - Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust ‌demand for its cystic fibrosis treatments.
The company expects its ‌annual revenue to be between $13.1 billion and $13.2 billion, compared with $12.95 billion to $13.1 billion previously. **** ysts on average expect 2026 revenue of $13.07 billion, according to data compiled by LSEG.
Vertex said its annual outlook excludes the pending Crinetics acquisition and that an updated forecast will be provided after the ‌deal closes, which is ⁠expected in the third quarter.
Here are more details:
• Vertex's $10 billion acquisition of Crinetics expands its reach beyond ⁠cystic fibrosis, adding endocrine disorders to a diversification strategy that already includes povetacicept in kidney, Casgevy in sickle cell and Journavx in pain, **** ysts had said.

#cystic #fibrosis

This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion in cash (the transaction hasn't closed yet). This is the largest acquisition in Vertex Pharmaceuticals' history, and it will enable the biotech giant to gain several promising pipeline candidates in endocrinology. Could there be an even more massive acquisition on the horizon in the industry? It's hard to say for sure, but if there is, Viking Therapeutics (NASDAQ: VKTX) may be the acquisition target.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
According to the U.S. Centers for Disease Control and Prevention, a little over 70% of adults in the country are overweight or obese. Excess weight is linked to a range of serious health problems, including diabetes, heart disease, and many others. Recent breakthroughs are helping address the issue. Anti-obesity medicines are allowing patients to lose weight and reduce their risk of developing a range of conditions. But this market is still in its early stages and is projected to expand rapidly over the next decade. According to some estimates, it will be worth $190 billion in 2035, compared to just $79 billion last year.
No wonder, then, that many pharmaceutical giants are looking to dip their toes in this **** e. But discovering and developing brand-new therapies from scratch in any field is expensive and time-consuming. That's why well-established drugmakers often prefer to acquire companies with promising mid and late-stage **** ets. That's where Viking Therapeutics comes in. The company's portfolio includes subcutaneous VK2735, currently in phase 3 clinical trials, as well as an oral version of the drug, which should begin late-stage studies by year-end. Further, Viking Therapeutics developed VK3019, another weight-loss candidate, which recently started phase 1 clinical trials.
Viking Therapeutics has one of the more impressive weight-loss pipelines among mid-cap biotechs, making it a great target for a pharmaceutical leader looking to fast-track the process and land some highly promising anti-obesity pipeline candidates overnight. Viking Therapeutics' phase 3 studies for VK2735 are expected to be completed by late 2027. If the results are very strong, the company's shares will soar, making it a much more expensive acquisition target. So, if any pharmaceutical giant is going to make a move, it probably will be before then.

#viking #NVIDIA #weight #promising

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now.
On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, effectively valuing the acquisition at around $10 billion or $8.8 billion after accounting for the cash.
Romaset/Shutterstock.com
The Boards of both companies approved the transaction unanimously, with completion projected for the third quarter of this year. Vertex plans to finance the acquisition through cash on hand and $4.5 billion in bridge financing from Bank of America and Morgan Stanley.
Following the announcement, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) garnered a lot of attention from **** ysts, who shared mixed opinions and revised their models based on this acquisition. On July 7, Baird increased its target price on the stock from $62 to $85, leading to an adjusted upside of more than 102%. The firm reiterated an Outperform rating on the stock.

Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best QQQ Stocks to invest in. On July 1, Vertex Pharmaceuticals announced that the US FDA approved the expanded use of its genetic therapy, CASGEVY, to treat children as young as 2 years old. This makes it the first and only approved gene therapy for patients of this age range suffering from sickle cell disease or transfusion-dependent beta thalassemia.
This regulatory milestone makes approximately 5,500 additional children in the US eligible for the one-time treatment. By providing earlier access to the therapy, clinicians hope to address the progression of these life-shortening diseases before significant, irreversible organ damage occurs.
Vertex Pharmaceuticals (NASDAQ:VRTX) established a network of over 75 authorized treatment centers across the U.S. to manage patient access and care. While this approval is specific to the US market, the company noted that regulatory reviews for similar label expansions are currently underway in the UK and the Kingdom of Saudi Arabia.
Vertex Pharmaceuticals (NASDAQ:VRTX) operates as a biotechnology company in the US, Europe, and internationally.
While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list.
TheFly reported on July 2 that UBS ******* yst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The ******* yst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors. UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
In other news, on July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash. The transaction received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs. The acquisition is expected to support Vertex's revenue growth, with the combined ******* ets projected to provide more than $5 billion in potential peak annual revenue.
Crinteics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Its key programs include PALSONIFY (paltusotine), an FDA- and EMA-approved oral treatment for acromegaly; atremelnant, a Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome; and a pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders, and this is what makes the company innovative.
While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, paying $85 per share in cash, with closing expected in the third quarter of 2026.
The acquisition adds PALSONIFY, an approved acromegaly treatment, and Atumelant, a Phase 3 candidate for congenital adrenal hyperplasia, expanding Vertex's rare disease pipeline.
Analysts have not yet rerated VRTX shares since the announcement, though H.C. Wainwright maintains a Buy rating with a Street-high $641 price target.
Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.

Genetic engineering and weight-loss innovation have become focal points for modern healthcare investors. Choosing between CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) depends on your appetite for risk and your belief in their distinct medical breakthroughs.
CRISPR Therapeutics uses gene-editing technology to address diseases at their genetic source, while Viking focuses on metabolic conditions such as obesity that affect millions globally. Both companies represent high-potential opportunities within the biotechnology ******* e, though they currently sit at very different stages of their respective commercial journeys.
CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company recently achieved a major milestone with the commercial launch of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. It operates under a strategic collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages global manufacturing and commercialization. Customer concentration like this adds a layer of risk to the business, as CRISPR Therapeutics relies on this partner for 60% of its profits and losses.
In FY 2025, revenue was about $3.5 million, representing a decrease of approximately 90% from the prior year. This decline is largely due to the transition from receiving one-time milestone payments to building out long-term commercial revenue streams from its approved products. The company reported a net loss of close to $581.6 million. Investing in biotech stocks requires an understanding of how these companies move from early research to global commercialization.
As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This ratio measures total debt relative to the equity shareholders have in the company, with a lower number indicating less reliance on borrowed money. Free cash flow was negative $345.9 million, representing the amount of cash a company generates after paying for capital expenditures.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash).
Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing.
Vertex's cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion.
Read Also:Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More US Children
The transaction was approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.

Conestoga Capital Advisors Exited Vertex (VRTX) as the Valuation No Longer Reflects a Favorable...

Conestoga Capital Advisors, an ******* et management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove energy prices up and created cautious global markets. Energy, Basic Materials, and Industrials performed